Amgen Inc. (AMGN) Stock Chart
NasdaqGSView the Amgen Inc. stock chart with market data, key statistics, volume, financial metrics, latest news, and exportable historical data.
Market data is for research and educational use only, not investment advice. Quotes may be delayed depending on the source and exchange; verify important prices with your broker or data provider.
Read the AMGN trend first
Use the range controls to compare short-term moves with the longer-term Amgen Inc. stock chart. A move that looks large on 1D can look routine on a 1Y or 5Y chart.
Check price with volume
Volume helps show whether a move happened with broad participation or thin trading. Compare recent bars with the average volume and news context before drawing conclusions.
Verify before acting
This page is built for research and education. Quotes, analyst fields, and news can be delayed or revised, so verify important prices with your broker or primary data provider.
Key Statistics
Financial Metrics
About Amgen Inc.
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including PROLIA, REPATHA, OTEZLA, ENBREL, EVENITY, XGEVA, TEPEZZA, BLINCYTO, NPLATE, TEZSPIRE, KYPROLIS, ARANESP, KRYSTEXXA AND VECTIBIX, MVASI, PAVBLU, UPLIZNA, IMDELLTRA/IMDYLLTRA, AMJEVITA/AMGEVITA, TAVNEOS, NEULASTA, LUMAKRAS/LUMYKRAS, RAVICTI, PARSABIV, AIMOVIG, WEZLANA/WEZENLA, AND PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; BEONE MEDICINES LTD. to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. The company was incorporated in 1980 and is headquartered in Thousand Oaks, California.
Related Charts
Data Definitions
Previous close
The most recent prior regular-session close reported by the market data source.
Day range
The source-reported high and low for the current or most recent trading session.
Volume
The number of shares, units, contracts, or asset quantity reported as traded during the period.
Moving averages
The 50-day and 200-day averages smooth recent prices to give quick trend context.
Market cap
A company or fund size estimate based on price and shares outstanding when source data is available.
P/E ratio
Price divided by earnings per share. It is most useful when compared with peers and growth expectations.